| Literature DB >> 29649231 |
Daniel Martinez-Marquez1, Ali Mirnajafizadeh2, Christopher P Carty3,4,5, Rodney A Stewart1.
Abstract
3D printing is an emergent manufacturing technology recently being applied in the medical field for the development of custom bone prostheses and scaffolds. However, successful industry transformation to this new design and manufacturing approach requires technology integration, concurrent multi-disciplinary collaboration, and a robust quality management framework. This latter change enabler is the focus of this study. While a number of comprehensive quality frameworks have been developed in recent decades to ensure that the manufacturing of medical devices produces reliable products, they are centred on the traditional context of standardised manufacturing techniques. The advent of 3D printing technologies and the prospects for mass customisation provides significant market opportunities, but also presents a serious challenge to regulatory bodies tasked with managing and assuring product quality and safety. Before 3D printing bone prostheses and scaffolds can gain traction, industry stakeholders, such as regulators, clients, medical practitioners, insurers, lawyers, and manufacturers, would all require a high degree of confidence that customised manufacturing can achieve the same quality outcomes as standardised manufacturing. A Quality by Design (QbD) approach to custom 3D printed prostheses can help to ensure that products are designed and manufactured correctly from the beginning without errors. This paper reports on the adaptation of the QbD approach for the development process of 3D printed custom bone prosthesis and scaffolds. This was achieved through the identification of the Critical Quality Attributes of such products, and an extensive review of different design and fabrication methods for 3D printed bone prostheses. Research outcomes include the development of a comprehensive design and fabrication process flow diagram, and categorised risks associated with the design and fabrication processes of such products. An extensive systematic literature review and post-hoc evaluation survey with experts was completed to evaluate the likely effectiveness of the herein suggested QbD framework.Entities:
Mesh:
Year: 2018 PMID: 29649231 PMCID: PMC5896968 DOI: 10.1371/journal.pone.0195291
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1QbD systematic product and process design development flow chart showing principal steps.
Adapted from [27, 34].
Fig 2Search strategy and selection of the studies.
Fig 3(a) Studies’ main objective, PU: Process understanding, PO: Prediction and optimization, RER: Reduction of experimental runs, DRM: development of robust manufacturing; (b) Percentage of reduction of experimental runs per paper; (c) QbD steps implemented in the reviewed studies.
The ideal eight quality dimensions of 3D printed bone implants.
| Quality approach | Dimension | Description |
|---|---|---|
| Performance | Each 3D printed bone prosthesis and scaffold is custom designed to restore the functional characteristics of patient’s bone, provide long term osseointegration, operate properly in normal conditions, and to last the required number of years for its purpose. | |
| Features | 3D printed bone prostheses have special features such as bioactive surfaces that promote bone ingrowth, a modulus of elasticity similar to the host bone, are specifically designed according to each customer’s geometry and functional characteristics, and possess a hierarchical macro, micro, and nano architecture that resembles bone structure. | |
| Reliability | Due to the fact that each prosthesis is custom made and fabricated with the latest technologies and materials, its life expectancy should match or exceed traditional bone prosthesis reliability and functional characteristics. In the case of bone scaffolds they are tuned to resorb based on each patient’s biological conditions to restore bone tissue. Moreover, The fabrication process of such products should be robust with minimum quality variations. | |
| Conformance | Each 3D printed bone prosthesis meets or exceeds medical device regulations. The design and fabrication processes are subjected to strict quality tests (control) to provide a product with zero defects (according to tolerances needed). | |
| Durability | Products are made with the best materials and technologies available, using a direct interaction with the customer to design custom bone implants that exceed the life expectancy of traditional bone prosthesis. | |
| Serviceability | Each client is unique. Therefore, the company is responsible for providing a personalized service where each client is involved in the prosthesis design process. Moreover, the company must meet all customer specifications on time and be responsible for any irregularity. Additionally, it is important to provide an easy and accessible service to any potential customer. | |
| Aesthetics | The product has the correct materials and appearance for the target market. The technologies used for the product design and fabrication allow a precise reconstruction of defects from trauma or surgery, providing a correct custom shape and superficial finish to achieve better cosmetic enhancement and functional rehabilitation. | |
| Perceived quality | In this case the client has a clear understanding about the product’s attributes, which can be found in medical performance reports and statistical data. |
Performance indicators of bone substitutes.
| Performance indicators | Definition |
|---|---|
| Osteoinductivity | Scaffold property where multipotential mesenchymal cells (MSCs) are stimulated or attracted to the material surface, to later differentiate into osteoblasts and form ectopic bone in vivo [ |
| Osteoconductivity | Scaffold capability to allow new cell colonization, bone ingrowth and blood-vessels formation [ |
| Osseointegration | Bond between new bone and the scaffold biomaterial [ |
Summary of the ideal CQA of custom 3D printed bone implants and scaffolds.
| Dimensional | Mechanical | Biological | Physicochemical | Functional |
|---|---|---|---|---|
| Match patient specific geometry | Low modulus of elasticity (resemble bone Young’s modulus) | Material purity | Biocompatibility | Patient’s bone characteristics |
| Macro surface geometrical accuracy | Shear/Compressive/tensile strength | Protein adhesion | Tuned resorption rate (biodegradable implants) | Muscle moment arms |
| Micro geometrical accuracy | Fatigue strength | Cell adhesion | Corrosion resistance (permanent implants) | Real life implant’s loading conditions |
| Nano geometrical accuracy | Hardness | Cell migration | Surface micro and nano topography | Implant’s bone interface contact forces |
| 3 dimensional structure | Toughness | Cell proliferation | High surface area | Implant’s soft tissue interface contact forces (metallic implants) |
| Pore size | Poisson's ratio | Mineralization | Bioactives | Customised rehabilitation program |
| Pore shape | Wear resistance | Control of inflammation | Resistance to sterilization process | |
| High pore interconnection | Antibacterial properties | Surface energy (wettability) | ||
| High percentage of porosity | Transport of nutrients and waste removal |
Fig 4General process flow diagram of custom 3D printed bone prostheses and scaffolds.
Fig 5Detailed process flow diagram for the design and fabrication of custom 3D printed bone prostheses and scaffolds.
Example of FDA recommended initial ISO 10993 biocompatibility evaluation endpoints for medical devices in contact with bone tissue and blood.
Adapted from [200].
| Device categorization | Biological effect | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nature of body contact | Contact duration | Cytotoxicity | Sensitization | Irrigation or intracutaneous reactivity | Acute systemic toxicity | Material-Mediated Pyrogenicity | Subacute/Subchronic Toxicity | Genotoxicity | Implantation | Hemocompatibility | Chronic Toxicity | Carcinogenicity | Reproductive/Developmental Toxicity | Degradation@ |
| A | X | X | X | O | O | |||||||||
| B | X | X | X | X | O | X | X | X | ||||||
| C | X | X | X | X | O | X | X | X | O | O | ||||
| A | X | X | X | X | O | O | X | X | ||||||
| B | X | X | X | X | O | X | X | X | X | |||||
| C | X | X | X | X | O | X | X | X | X | O | O | |||
X = ISO 10993–1:2009 recommended endpoints for consideration*
O = Additional FDA recommended endpoints for consideration*
Note * All X’s and O’s should be addressed in the biological safety evaluation, either through the use of existing data, additional endpoint-specific testing, or a rationale for why the endpoint does not require additional assessment.
Note @ Degradation information should be provided for any devices, device components, or materials remaining in contact with tissue that are intended to degrade.
Linking CPP activities with CQA groups.
| Critical process parameters | Affected CQA |
|---|---|
| Patient’s Medical Record | Functional |
| CT Protocol | Dimensional |
| Image Acquisition | Dimensional |
| Image Segmentation | Dimensional, Functional |
| 3D Volumetric Reconstruction | Dimensional, Functional |
| Geometrical Modelling | Dimensional, Functional |
| Computational NMS model | Dimensional, Mechanical, Biological, Functional |
| Lattice design process | Dimensional, Mechanical, Biological |
| MFEA | Mechanical, Functional |
| STL conversion | Dimensional |
| Fabrication | Dimensional, Mechanical, Biological |
| Material recycling | Dimensional, Mechanical, Biological |
| Cleaning and Finishing | Dimensional, Mechanical, Biological, Physicochemical |
| Surface modification | Dimensional, Mechanical, Biological, Physicochemical |
| Sterilization and packaging | Dimensional, Mechanical, Biological, Physicochemical |
Linking CMA with CQA groups.
| Critical material attributes | Affected CQA |
|---|---|
| Recycling | Dimensional, Mechanical, Biological |
| Mix | Mechanical, Biological |
| Composition | Mechanical, Biological, Physicochemical |
| Storing | Mechanical, Biological, Physicochemical |
| Traceability | Mechanical, Biological, Physicochemical |
| Sterilizing method | Mechanical, Biological, Physicochemical |
| Mechanical | Mechanical, Biological |
| Biological | Mechanical |
| Physicochemical | Mechanical, Biological, Physicochemical |
| Material form | Mechanical |
| Necessary energy for binding | Mechanical, Biological, Physicochemical |
Fig 6Flow chart of selected quality risk assessment tools, and scope of present study.
Fig 7Ishikawa diagram, summary of causes of non-conformity to the quality of custom 3D printed bone implants.
RBS of the causes of quality non-conformity in custom 3D printed bone prostheses.
| Level 0 | Level 1 | Level 2 | Level | |||
|---|---|---|---|---|---|---|
| 1.1.1 | Difficulty to implement CT protocol. Use of wrong CT parameters | • Model dimension distortion | [ | |||
| 1.1.2 | Slice increment is too large or the slice thickness is too big | • Stair step effect | [ | |||
| 1.1.3 | Small radiation dose compared to slice thickness | • Noise in images leads to wrong 3D reconstruction | [ | |||
| 1.2.1 | Wrong gantry tilt | • Distortion of 3D volumetric reconstruction | [ | |||
| 1.2.2 | Patient involuntary movement during CT scan | • Discrepancies in CT images | [ | |||
| 1.2.3 | Metallic artefacts | • Distortion of 3D volumetric reconstruction | [ | |||
| 1.2.4 | Compressed file or wrong file format | • Discrepancies in CT images | [ | |||
| 1.3.1 | Incorrect thresholding or algorithm processing | • Fail to capture thin bone (mainly in facial structures such as orbital walls) | [ | |||
| 1.4.1 | Incorrect mesh generation | • Dimensional variations in the model | [ | |||
| 1.4.2 | Incorrect mesh optimization or refinement | • Poor and rough surface quality | [ | |||
| 1.4.3 | Software used | • Dimensional variations in the model | [ | |||
| 1.4.4 | Conversion from DICOM to STL. | • Dimensional variations in the model | [ | |||
| 1.5.1 | Software: file conversion between STL and CAD | • Loss of part details such as thin bone of the orbital wall, due to incomplete data transfer during file conversion | [ | |||
| 1.5.2 | Wrong freeform approximation | • Stair step effect | [ | |||
| 1.5.3 | Wrong implant/scaffold design | • Inclusions of particles inside closed cavities | [ | |||
| 1.5.4 | Wrong design (surface and unit cell) | • Wrong implant mechanical properties for soft-hard tissue contact adaptation (modulus of elasticity) | [ | |||
| 1.5.5 | Close tolerances | • Wrong tolerances of the fabricated part due to tolerances being geometry dependent | [ | |||
| 1.5.6 | Wrong scaffold pore design (unit cell), such as size, shape, and interconnection | • Insufficient cell density and bone regeneration | [ | |||
| 1.5.7 | Insufficient support structures | • Part or surface damage | [ | |||
| 1.5.8 | Wrong tolerances | • Fusion of trapped particles | [ | |||
| 1.5.9 | Incorrect material or design parameters | • Part shrinkage and distortion | [ | |||
| 1.5.10 | Incorrect part orientation for fabrication | • Stair step effect | [ | |||
| 1.6.1 | Discrepancies between computational simulation and experimental data, due to inaccurate micro precision in fabrication | • Inaccurate mechanical and biological properties as well as fluid dynamics | [ | |||
| 1.6.2 | Errors in joint kinematics estimation | • May affect load computations. | [ | |||
| 1.6.3 | Inaccurate estimation of bone contact forces | • Implant failure | [ | |||
| 1.6.4 | Inaccurate estimation of bone/implant contact forces | • Inaccurate estimation of micromotion and stability between bone and implant | [ | |||
| 1.6.5 | Incorrect FEA parameters | • Wrong design | [ | |||
| 1.7.1 | Inaccurate fabrication of micro-features such as pore size and shape | • Reduced biological and mechanical performance | [ | |||
| 1.7.2 | Localised material heating and cooling. | • Thermal warping or dimensional distortion | [ | |||
| 1.7.3 | Material contamination | • Defective product due to impurities higher than max limits | [ | |||
| 1.7.4 | Part overhanging features | • Undesirable defects | [ | |||
| 1.7.5 | Residual polymerization | • Inaccurate parts | [ | |||
| 1.7.6 | Fabrication layer thickness. | • Stair step effect in Z direction | [ | |||
| 1.7.7 | Large scanning spacing or hatch spacing | • Stair step effect in X and Y directions, leading to dimensional inaccuracy | [ | |||
| 1.7.8 | Low scanning spacing or hatch spacing | • Slowdown the fabrication process | [ | |||
| 1.7.9 | Laser diameter | • Omission of part fine details | [ | |||
| 1.7.10 | High laser temperature | • Part shrinkage | [ | |||
| 1.7.11 | Low laser temperature | • Slow fabrication process | [ | |||
| 1.7.12 | Powder bed temperature | • Variation on part density and mechanical properties | [ | |||
| 1.713 | Material thermal and phase change effects | • Part shrinkage | [ | |||
| 1.7.14 | Incorrect cooling cycle | • Thermal warping | [ | |||
| 1.7.15 | Part exposition to atmosphere when still at high temperature | • Changes in colour | [ | |||
| 1.7.16 | Different professional terminologies | • Defective product | [ | |||
| 1.7.17 | Process documentation and expression of documents | • Defective product. | [ | |||
| 1.7.18 | Communication method (technology used) | • Defective product | [ | |||
| 1.7.19 | Difficulty to monitor fabrication process | • Can leads to reduced quality | [ | |||
| 1.7.20 | Inaccurate/inefficient material recycling method | • In powdered materials this can lead to larger particle size, contamination, and oxidation. | [ | |||
| 1.8.1 | Removal of supporting structures | • Part damage | [ | |||
| 1.8.2 | Part cleaning (Sand blasting) | • Part damage (changes in part dimensions) | [ | |||
| 1.8.3 | Surface modification method | • Discrepancy in mechanical behaviour | [ | |||
| 1.9.1 | Surface topography modification parameters. | • Wrong biological performance | [ | |||
| 1.9.2 | Selection of surface topography modification method. | • Different biological performance | [ | |||
| 1.10.1 | Difficulty locating land marks to measure the model. | • Wrong measurement of model | [ | |||
| 1.10.2 | Human error during measurement | • Wrong measurement of model | [ | |||
| 1.10.3 | Dimensional validation method | • Wrong measurement of model | [ | |||
| 1.11.1 | Wrong selection of sterilization method | • Implant dimensional changes | [ | |||
| 1.11.2 | Inefficient sterilization | • Biological hazard, such as viral and microbial transmission | [ | |||
| 2.1 | Building speed variation | • Inaccurate part dimensions | [ | |||
| 2.2 | Misalignment of positioning system | • Inaccurate part dimensions | [ | |||
| 2.3 | Part movement during fabrication | • Inaccurate part dimensions | [ | |||
| 2.4 | Clogged print head or Nuzzle | • Damaged or defective part | [ | |||
| 2.5 | Worn coater blade | • Low surface quality | [ | |||
| 2.6 | Short of feed powder | • Low surface quality | [ | |||
| 2.7 | Laser failure | • Internal defects | [ | |||
| 2.8 | Random errors in parts made by the same process, using the same material and parameters | • No identical implants | [ | |||
| 2.9 | Localised material heating and cooling | • Thermal warping | [ | |||
| 2.10 | Machine maintenance | • Equipment failure | [ | |||
| 2.11 | Machine calibration | • Dimensional inaccuracies | [ | |||
| 2.12 | Machine parameters | • Dimensional accuracy | [ | |||
| 2.13 | Difficulty to monitor fabrication process | • Can leads to reduced quality | [ | |||
| 3.1 | Poor communication between design team and surgeon | • Inaccurate product | [ | |||
| 3.2 | Misinterpretation of the transferred knowledge | • Defective product | [ | |||
| 3.3 | Availability of high qualified personal in the necessary professional skills | • Can lead to low performance | [ | |||
| 3.4 | Material Suppliers | • Low material quality | [ | |||
| 3.5 | Fabrication/design suppliers | • Low quality | [ | |||
| 3.6 | Deficient personnel traits and training | • High chances of mistakes during design and fabrication processes, leading to low quality products | [ | |||
| 3.7 | Lack of training and experience due to introduction of new technologies and surgical methods (medical doctor) | • Inaccurate use of implant | [ | |||
| 3.8 | Low stakeholders involvement during the product development and design process | • Incorrect product characteristics | [ | |||
| 3.9 | Limited knowledge of patient’s current health condition an biological characteristics | • Poor preoperative planning | [ | |||
| 4.1 | Material stored under sun light and humid places | • Damage material and contamination | [ | |||
| 4.2 | Expired material | • Inconsistent mechanical properties | [ | |||
| 4.3 | Wrong material mix (% of virgin and % of recycled) | • Inconsistent mechanical properties | [ | |||
| 4.4 | Wrong powder particle size | • Incorrect particle bonding, | [ | |||
| 4.5 | Wrong material characteristics and contamination | • Inconsistent mechanical properties, not compliance with regulations | [ | |||
| 4.6 | Wrong material selection | • Reduced implant biocompatibility | [ | |||
| 4.7 | Material reuse times | • Can lead to contamination | [ | |||